RNA-Targeted Small Molecule Drug Discovery
Novel Strategies Using Small Molecules to Target RNA Structure, Binding, Interactions, and Function
April 19, 2027 ALL TIMES PDT
RNA molecules have complex, dynamic structures which make them challenging drug targets. However, advances in elucidating RNA structure, function, and interactions have led to finding small molecules to target RNA for therapeutic intervention. AI models and machine learning algorithms have also helped predict RNA-ligand interactions and optimize compounds with enhanced stability, oral bioavailability, and better drug-like properties. However, identifying the right disease-causing RNA and evaluating the downstream physiological responses after small molecule binding can be quite challenging. Cambridge Healthtech Institute’s symposium on RNA-Targeted Small Molecule Drug Discovery will highlight some of the early discovery and preclinical work being done to target mRNA, non-coding RNA, microRNA, and other modalities for cardiometabolic, infectious, and neurologic disorders, oncology, and other genetic indications.
Preliminary Agenda

RNA-TARGETED THERAPIES

Chairperson's Remarks

Jay Schneekloth Jr., PhD, Professor, Department of Biological Chemistry, University of Michigan , Professor , Biological Chemistry , University of Michigan

Leveraging Structural Ensembles to Modulate the Function of RNAs in Cells

Photo of Jay Schneekloth Jr., PhD, Professor, Department of Biological Chemistry, University of Michigan , Professor , Biological Chemistry , University of Michigan
Jay Schneekloth Jr., PhD, Professor, Department of Biological Chemistry, University of Michigan , Professor , Biological Chemistry , University of Michigan

Targeting RNA remains a frontier of medicinal chemistry, and often a detailed structural understanding of a given RNA is lacking. In this talk, I will discuss our group's efforts to bring rational design to RNA-targeting molecules, including leveraging structure, conformational ensembles, machine learning, and new high throughput screening methodologies to identify selective, RNA-targeted probe molecules.

Building a Platform for the Identification of RNA Splice Modulators

Photo of James Harvey, PhD, Scientific Director, Medicinal Chemistry, Biogen , Scientific Director , Medicinal Chemistry , Biogen
James Harvey, PhD, Scientific Director, Medicinal Chemistry, Biogen , Scientific Director , Medicinal Chemistry , Biogen

RNA splice modulation represents a promising therapeutic approach that expands the range of genetically validated targets accessible to small-molecule drug discovery. This presentation describes the development of an integrated discovery platform that has enabled the identification of potent, selective, and brain-penetrant compounds while advancing understanding of the factors that drive efficacy and selectivity. These efforts highlight the potential of RNA-targeted small molecules to create new opportunities for precision medicine.

FEATURED PRESENTATION: In Cell High-throughput Evaluation of RNA-Binding Protein Small molecule Ligands with STAMP

Photo of Eugene Yeo, PhD, MBA, Professor, Cellular and Molecular Medicine, University of California, San Diego; Founding Member, Institute for Genomic Medicine , Professor , Cellular Molecular Medicine , University of California, San Diego
Eugene Yeo, PhD, MBA, Professor, Cellular and Molecular Medicine, University of California, San Diego; Founding Member, Institute for Genomic Medicine , Professor , Cellular Molecular Medicine , University of California, San Diego

I will discuss our development of  RNA-binding protein fusion RNA-base editing-dependent measurements to study small molecule ligands. Our technology enables mid-to-high throughput evaluation of these ligands for transcriptome-wide readouts. I will discuss our analytics on these datasets.

Understanding and Mapping the Exon Target Space of Splicing Modifying Compounds

Photo of Philipp Ottis, PhD, Principal Scientist II, Chemical Biology, Novartis Biomedical Research , Principal Scientist II , Chemical Biology , Novartis Biomedical Research
Philipp Ottis, PhD, Principal Scientist II, Chemical Biology, Novartis Biomedical Research , Principal Scientist II , Chemical Biology , Novartis Biomedical Research

Small-molecule splicing modulators stabilize U1-snRNA interactions at weak 5' splice sites, yet their target specificity remains incompletely understood. We define sequence and mRNA structural requirements governing exon responsiveness and use mutant U1-snRNAs to genetically model splice-site stabilization beyond current chemical matter. Transcriptome-wide profiling reveals a broad landscape of inducible exons, while integration of sequence, structural, and transcriptomic features enables prediction of exon amenability and expands opportunities for therapeutic splicing modulation.

Mechanistic Insights into Splicing Modulation to Define RNA-Small Molecule Interactions & Unlock Targetable Splice Sequences

Christopher Trotta, PhD, Vice President & Senior Director, Biology, PTC Therapeutics Inc. , VP & Senior Director , Biology , PTC Therapeutics Inc.

Using cryo-EM of the complete human U1 snRNP engaged with an authentic 5′ splice site and a clinically relevant splicing modulator, we show that the compound binds a composite RNA–protein pocket and selects a productive conformational state of the ribonucleoprotein, with local engagement at the splice site allosterically coupled to a long-range rearrangement within the U1 snRNP complex. The structure rationalizes the sequence selectivity, binding stability, and molecular specificity that define this therapeutic class and offers a foundation for the rational design of next-generation splicing modulators.

BRAINSTORMING SESSION

Discussion on the Advantages and Challenges of Pursuing RNA as a Drug Target Using Small Molecules


For more details on the conference, please contact:
Tanuja Koppal, PhD
Senior Conference Director
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners